Predicting diabetes

Prevention of Type 2 Diabetes: From Science to Therapy

Volumn , Issue , 2012, Pages 81-102

  Dankner, Rachel ^a,b,c   Roth, Jesse ^c,d  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872229109     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3314-9_6     Document Type: Chapter

References (86)

1. Jesudason DR, Dunstan K, Leong D, Wittert GA. Macrovascular risk and diagnostic criteria for type 2 diabetes: implications for the use of FPG and HbA(1c) for cost-effective screening. Diabetes Care. 2003;26(2):485-90.
2. Wong TY, Liew G, Tapp RJ, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008;371:736-43.
3. Toth MJ, Tchemof A. Lipid metabolism in the elderly. Eur J Clin Nutr. 2000;54 Suppl 3:121-5.
4. Nakao C, Ookawara T, Sato Y, et al. Extracellular superoxide dismutase in tissues from obese (olbob) mice. Free Radic Res. 2000;33:229-41.
5. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114:1752-61.
6. Park J, Chung JJ, Kim JB. New evaluations of redox regulating system in adipose tissue of obesity. Diabetes Res Clin Pract. 2007;77 Suppl 1:S11-6.
7. Brown TM, Voeks JH, Bittner V, Safford MM. Variations in prevalent cardiovascular disease and future risk by metabolic syndrome classification in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Am Heart J. 2010;159(3):385-91.
8. Rabinowitz D, Zierler KL. Forearm metabolism in obesity and its response to intra-arterial insulin: characterization of insulin resistance and evidence for adaptive hyperinsulinism. J Clin Invest. 1962;41:2173-81.
9. Sicree RA, Zimmet PZ, King HO, et al. Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 yr. Diabetes. 1987;36(2):179-86.
10. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113(12):909-15.
11. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993;329(27):1988-92.
12. Weyer C, Hanson RL, Tataranni PA, et al. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes. 2000;49(12):2094-101.
13. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest. 1985;75:809-17.
14. Dankner R, Chetrit A, Shanik MH, et al. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care. 2009;32(8):1464-6.
15. Haffner SM, Stern MP, Mitchell BD, et al. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes. 1990;39(3):283-8.
16. Bj0rnholt JV, Erikssen G, Liest0l K K, et al. Prediction of type 2 diabetes in healthy middle- aged men with special emphasis on glucose homeostasis. Results from 22.5 years’ follow-up. Diabet Med. 2001;18(4):261-7.
17. Tirosh A, Shai I, Tekes-Manova D, etal., IsraeliDiabetesResearchGroup. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med. 2005;353(14):1454-62.
18. Nguyen QM, Srinivasan SR, Xu JH, et al. Fasting plasma glucose levels within the normoglycemic range in childhood as a predictor of prediabetes and type 2 diabetes in adulthood. The Bogalusa Heart Study. Arch Pediatr Adolesc Med. 2010;164(2):124-8.
19. Gutt M, Davis CL, Spitzer SB, et al. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract. 2000;47(3):177-84.
20. Hanley AJ, Williams K, Gonzalez C, et al., San Antonio Heart Study; Mexico City Diabetes Study; Insulin Resistance Atherosclerosis Study. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes. 2003;52(2): 463-9.
21. Rutter MK, Wilson PWF, Sullivan LM, et al. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation. 2008;117:1003-9.
22. Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44(12):1386-91.
23. Dankner R, Abdul-Ghani MA, Gerber Y, et al. Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev. 2007;23(7):551-8.
24. Sato KK, Hayashi T, Harita N, et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes. Diabetes Care. 2009;32:644-6.
25. Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes. 2011;60:298-305.
26. Ferrannini E, Nannipieri M, Williams K, et al. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes. 2004;53(1):160-5.
27. Lyssenko V, Almgren P, Anevski D, et al., Botnia study group. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2005;54(1):166-74.
28. Mason CC, Hanson RL, Knowler WC. Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes. 2007;56:2054-61.
29. Tabak AG, Jokela M, Akbaraly TN, et al. Trajectories of glycemia, insulin sensitivity and insulin secretion preceding the diagnosis of type 2 diabetes: the Whitehall II study. Lancet. 2009;373:2215-21.
30. Klein S, Allison DB, Heymsfield SB, Association for Weight Management and Obesity Prevention; NAASO; Obesity Society; American Society for Nutrition; American Diabetes Association; Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America’s health. Diabetes Care. 2007;30:1647-52.
31. Warne DK, Charles MA, Hanson RL, et al. Comparison of body size measurements as predictors of NIDDM in Pima Indians. Diabetes Care. 1995;18(4):435-9.
32. Stevens J, Couper D, Pankow J, et al. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res. 2001;9(11):696-705.
33. Rolandsson O, Hagg E, Nilsson M, et al. Prediction of diabetes with body mass index, oral glucose tolerance test and islet cell autoantibodies in a regional population. J Intern Med. 2001;249(4):279-88.
34. Wannamethee SG, Papacosta O, Whincup PH, et al. Assessing prediction of diabetes in older adults using different adiposity measures: a 7 year prospective study in 6,923 older men and women. Diabetologia. 2010;53(5):890-8.
35. Preis SR, Pencina MJ, D’Agnostino RB. Abstract 1469: neck circumference and development of cardiovascular disease risk factors in the Framingham heart study. Circulation. 2009;120:S509.
36. Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk. Diabetes Care. 2011;34(8):1741-8.
37. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36:232-40.
38. Dotevall A, Johansson S, Wilhelmsen L, et al. Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study. Diabet Med. 2004;21(6):615-22.
39. Tirosh A, Shai I, Bitzur R, et al. Changes in triglyceride levels over time and risk of type 2 diabetes in young men. Diabetes Care. 2008;31(10):2032-7.
40. Yaouanq JM. Diabetes and haemochromatosis: current concepts, management and prevention. Diabete Metab. 1995;21(5):319-29.
41. Salonen JT, Tuomainen TP, Nyyssonen K, et al. Relation between iron stores and non-insulin dependent diabetes in men: case-control study. Bmj. 1998;317:727.
42. Jiang R, Manson JE, Meigs JB, et al. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. Jama. 2004;291(6):711-7.
43. Forouhi NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007;50(5):949-56.
44. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(6): 1889-95.
45. Sattar N, McConnachie A, Ford I, et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes. 2007;56(4):984-91.
46. Hanley AJG, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes. The Insulin Resistance Atherosclerosis Study. Diabetes. 2004;53:2623-32.
47. Malmstrom R, Taskinen MR, Karonen SL, et al. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia. 1996;39:993-6.
48. Zimmet P, Hodge A, Nicolson M, et al. Serum leptin concentration, obesity, and insulin resistance in Western Samoans: cross sectional study. Bmj. 1996;313:965-9.
49. Shih LY, Liou TH, Chao JC, et al. Leptin, superoxide dismutase, and weight loss: initial leptin predicts weight loss. Obesity (Silver Spring). 2006;14(12):2184-92.
50. McNeely MJ, Boyko EJ, Weigle DS, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care. 1999;22(1):65-70.
51. Schmidt MI, Duncan BB, Vigo A, et al., ARIC Investigators. Leptin and incident type 2 diabetes: risk or protection? Diabetologia. 2006;49(9):2086-96.
52. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595-9.
53. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose- derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86(8):3815-9.
54. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57-8.
55. Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care. 2003;26(7):2015-20.
56. Duncan BB, Schmidt MI, Pankow JS, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004;53(9):2473-8.
57. Snijder MB, Heine RJ, Seidell JC, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care. 2006;29(11):2498-503.
58. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-9.
59. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342: 836-43.
60. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286(3):327-34.
61. Freeman DJ, Norrie J, Caslake MJ, et al., West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51(4):1131-7.
62. Festa A, D’Agostino R Jr, Tracy RP, et al., Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131-7.
63. Festa A, Williams K, Tracy RP, et al. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation. 2006;113(14):1753-9.
64. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. Jama. 2006;295(11):1288-99.
65. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009 Sep 17;361(12):1152-63. Epub 2009 Aug 5.
66. Reaven GM. Banting lecture: role of insulin resistance in human disease. Diabetes. 1988;37: 1595-607.
67. Lorenzo C, Okoloise M, Williams K, et al., San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26(11):3153-9.
68. Stern MP, Williams K, Gonzalez-Villalpando C, et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care. 2004;27(11):2676-81.
69. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31:1898-904.
70. Urdea M, Kolberg J, Wilber J, et al. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J Diabetes Sci Technol. 2009;3(4):748-55.
71. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790-7.
72. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-31.
73. Schulze MB, Hoffmann K, Boeing H, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care. 2007;30:510-5.
74. Bergmann A, Li J, Wang L, et al. A simplified Finnish diabetes risk score to predict type 2 diabetes risk and disease evolution in a German population. Horm Metab Res. 2007;39(9):677-82.
75. Hippisley-Cox J, Coupland C, Robson J, et al. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. Bmj. 2009;338:b880.
76. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359(21):2208-19.
77. Schulze MB, Weikert C, Pischon T. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam study. Diabetes Care. 2009;32:2116-9.
78. Jensen AC, Barder A, Kumari M, et al. Associations of common genetic variants with age- related changes in fasting and postload glucose. Evidence from 18 years of follow-up of the Whitehall II Cohort. Diabetes. 2011;60(5):1617-23.
79. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Bmj. 1994;308:1323-8.
80. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997;20(5):785-91.
81. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7): 1183-97.
82. Jonas JB, Xu L, Xie XW, et al. Relationship between fasting glucose and retinopathy for diagnosis of diabetes: results from a population-based study in urban and rural China. Retina. 2010;30(8): 1223-7.
83. Bergman M. Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes Metab Res Rev. 2010;26:3-6.
84. Toshikazu S, Makoto W, Junko N, et al., Zensharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels. A Randomized Controlled Trial. Arch Intern Med. 2011; 171 (15): 1352-60.
85. Abdul-Ghani MA, Defronzo RA. Plasma glucose concentration and prediction of future risk of type 2 diabetes. Diabetes Care. 2009;32 Suppl 2:S194-8.
86. Dankner R, Danoff A, Roth J. Can ‘personalized diagnostics’ promote earlier intervention for dysglycaemia? Hypothesis ready for testing. Diabetes Metab Res Rev. 2010;26:7-9.